Form 4: Y-mAbs Therapeutics Director David N. Gill Reports Stock and Option Transactions

Director David N. Gill reports acquisition of restricted stock units and stock options, along with disposal of common stock.

Summary

• On June 11, 2024, David N. Gill, a director of Y-mAbs Therapeutics, Inc., reported transactions involving the company's securities.
• Gill acquired 3,495 restricted stock units (RSUs) and disposed of 5,825 shares of common stock.
• Additionally, Gill acquired 14,545 stock options with an exercise price of $12.01.
• Following these transactions, Gill beneficially owns 5,825 shares of common stock and 14,545 stock options.
• The RSUs vest on the earlier of the first anniversary of the grant date or the date immediately preceding the 2025 annual meeting, contingent upon continued service.
• The stock options vest in equal monthly installments until the first anniversary of the grant date, also contingent upon continued service, and are exercisable immediately upon vesting.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions by a director, with both acquisitions and disposals of stock. The equity grants are a positive sign, but the stock disposal tempers the overall sentiment.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedules for the RSUs and stock options incentivize continued service to the company.

Negatives

• The disposal of 5,825 shares of common stock by a director could be perceived negatively by investors, although the reason for disposal is not disclosed.

Risks

• The value of the RSUs and stock options is contingent on the future performance of Y-mAbs Therapeutics' stock.
• The vesting of the RSUs and stock options is dependent on the director's continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of RSUs and stock options is tied to future service and the company's annual meeting in 2025.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The acquisition of equity by a director is generally viewed positively, as it aligns their interests with those of shareholders.

Comparison to Industry Standards

• Equity grants to directors are a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.
• Vesting schedules for stock options and RSUs typically range from one to four years, with monthly or quarterly vesting increments.
• The specific terms of the equity grants, such as the exercise price and vesting schedule, are generally comparable to those offered by similar-sized biotechnology companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders' perception of the company, depending on how they interpret the director's stock disposal.
• The equity grants incentivize the director to contribute to the company's success, potentially benefiting all stakeholders.

Key Dates